Cresco Labs: Analyst Q4 2020 Consensus Expectations

Cresco Labs (CSE: CL) announced that they will be reporting their fourth quarter and year-end financials pre-market on March 25th. Analysts have a consensus C$22.22 12-month price target on the company, via a total of 16 analysts, with four analysts having a strong buy rating and the other 11 have buy ratings and one analyst has a hold rating. The street high comes from Stifel-GMP with a C$36 price target, and the lowest target comes from Roth Capital with a C$17.50 price target.

Sixteen analysts have revenue estimates for the fourth quarter. The mean between all 16 is U$161.38 million; this number has been revised downwards from U$162.50 million at the start of the year. Needham & Co currently has the highest revenue estimate with U$167.8 million, while the lowest comes from Piper Sandler with a U$156.1 million estimate.

For the full year, the average revenue estimate between 16 analysts is currently U$475.52 million. This number has been revised downwards from U$475.52 million at the start of the year. The street high comes from Needham & Co with a U$481.70 full-year revenue estimate, while the lowest comes from Piper Sandler with a U$470 million estimate.

Onto EBITDA estimates, there are currently 14 analysts who have fourth-quarter EBITDA estimates. The mean is currently U$48.06 million, with this number roughly the same since the start of the year. Street high goes to Needham & Co with a U$52,14 million EBITDA estimate and the lowest being ATB Capital with a U$42.20 million estimate.

For the full year, the current EBITDA mean across 12 analysts is U$114.13 million. This number is roughly the same since the start of the year. Needham & Co currently has the highest full-year estimate at U$118.21 million and the lowest being Benchmark with a U$158 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Fixing Heart Disease Tied to Sudden Death in Young People | David Elsley – Cardiol Therapeutics

Gold is Not Done | Saf Dhillon – Questcorp Mining

First Phosphate: Building a North American Battery Supply Chain from the Ground Up

Recommended

Total Metals Secures High Grade Critical Minerals Property In Northwestern Ontario

Discovery at Luis Hill Prompts Acceleration of Phase 2 Program for Questcorp

Related News

Cineplex: Consensus Price Target Sees Marginal Lift Post Earnings

Cineplex Inc. (TSX: CGX) reported their first-quarter financial results last week, with the company reporting...

Monday, May 10, 2021, 10:41:00 AM

BMO Downgrades Activision Blizzard, Says To “Take Profits, Step To Sidelines”

BMO’s analyst Gerrick Johnson is downgrading Activision Blizzard (NASDAQ: ATVI) to Market Perform and reducing...

Tuesday, October 13, 2020, 04:24:00 PM

Green Thumb: Despite Earnings Beat, Analysts Lower Targets On Sector Headwinds

On August 3, Green Thumb Industries (CSE: GTII) reported its second quarter financial results. The...

Saturday, August 6, 2022, 05:18:00 PM

Green Thumb: Canaccord Raises Price Target To $52 Following Q4 Results

On March 17th, Green Thumb Industries (CSE: GTII) reported their fourth quarter and year end...

Saturday, March 20, 2021, 02:41:00 PM

Psyched Wellness: Canaccord Pens “Future In Fungi Report”

Yesterday morning, Canaccord Genuity released a primer into five psychedelic companies that they “believe could...

Tuesday, March 9, 2021, 11:49:00 AM